Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 5;17(9):e91658.
doi: 10.7759/cureus.91658. eCollection 2025 Sep.

Efficacy and Safety of Colchicine in Reducing Reperfusion Injury Among Patients With ST-Segment Elevation Myocardial Infarction (STEMI): A Systematic Review and Clinical Appraisal

Affiliations
Review

Efficacy and Safety of Colchicine in Reducing Reperfusion Injury Among Patients With ST-Segment Elevation Myocardial Infarction (STEMI): A Systematic Review and Clinical Appraisal

Archana Dhami et al. Cureus. .

Abstract

This systematic review evaluated the efficacy and safety of colchicine in reducing ischemia-reperfusion injury among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. A comprehensive literature search across five databases identified 92 records, with five studies meeting the inclusion criteria, encompassing 390 patients. The included studies comprised randomized controlled trials and prospective studies investigating various colchicine dosing regimens, from short-term high-dose protocols to prolonged maintenance therapy. Primary outcomes included infarct size, inflammatory biomarkers, major adverse cardiovascular events, and safety profiles. Results demonstrated heterogeneous findings across studies. While one trial showed trends toward reduced inflammatory markers such as NLRP3 inflammasome activity, others failed to demonstrate significant reductions in reperfusion injury events or infarct size. Notably, the COVERT-MI trial revealed an unexpected threefold increase in left ventricular thrombus formation with colchicine therapy, raising safety concerns. Gastrointestinal side effects were also consistently reported across studies. The evidence suggests that the anti-inflammatory properties of colchicine may not translate into clinically meaningful cardioprotection in the acute phase of STEMI. Current data do not support routine colchicine administration for reperfusion injury reduction in STEMI patients undergoing primary percutaneous coronary intervention, highlighting the need for larger, well-designed trials with standardized protocols and longer follow-up periods to definitively establish its role in acute myocardial infarction management.

Keywords: colchicine; inflammasome; ischemia-reperfusion; left ventricular thrombus; primary percutaneous coronary intervention; reperfusion injury; st-segment elevation myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. PRISMA diagram showing the study selection process
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

References

    1. Comprehensive review of ST-segment elevation myocardial infarction: understanding pathophysiology, diagnostic strategies, and current treatment approaches. Elendu C, Amaechi DC, Elendu TC, et al. Medicine (Baltimore) 2023;102:0. - PMC - PubMed
    1. Myocardial preservation during primary percutaneous intervention: it's time to rethink? Yadav R, Yadav S, Goswami KC, Yadav G. Indian Heart J. 2021;73:395–403. - PMC - PubMed
    1. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Zhang M, Liu Q, Meng H, et al. Signal Transduct Target Ther. 2024;9:12. - PMC - PubMed
    1. Cell biology of ischemia/reperfusion injury. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Int Rev Cell Mol Biol. 2012;298:229–317. - PMC - PubMed
    1. Inflammation in myocardial ischemia/reperfusion injury: underlying mechanisms and therapeutic potential. Francisco J, Del Re DP. Antioxidants (Basel) 2023;12:1944. - PMC - PubMed

LinkOut - more resources